Sep 30, 2021

Mesa Labs Q2 2022 Earnings Report

Mesa Labs reported an increase in revenues and net income but a decrease in operating income for Q2 2022.

Key Takeaways

Mesa Laboratories reported a 12% increase in revenues to $35.84 million for the second quarter of fiscal year 2022. Operating income decreased by 6% to $4.201 million, while net income increased by 39% to $3.720 million, or $0.70 per diluted share.

Revenues increased by 12% compared to the same quarter last year.

Operating income decreased by 6% compared to the same quarter last year.

Net income increased by 39% compared to the same quarter last year.

Sterilization and Disinfection Control division saw 21% organic growth.

Total Revenue
$35.8M
Previous year: $31.9M
+12.5%
EPS
$1.87
Previous year: $1.91
-2.1%
Gross Profit
$23.1M
Previous year: $21.3M
+8.7%
Cash and Equivalents
$278M
Previous year: $240M
+16.0%
Free Cash Flow
$3.5M
Previous year: $9.86M
-64.5%
Total Assets
$609M
Previous year: $589M
+3.4%

Mesa Labs

Mesa Labs

Mesa Labs Revenue by Segment

Forward Guidance

Mesa Labs anticipates continued volatility from the COVID pandemic, regulatory and tax environment changes, and strong competition for talent.

Positive Outlook

  • The Mesa Way and strong underlying markets have resulted in robust year to date organic growth of 14% versus 1H21.
  • Combination with Agena Bioscience creates new opportunities within Clinical Genomics tools.
  • Reinforces core strategy of being a leader in life sciences and quality control tools.
  • Adds a genomic complement to protein analytics capabilities.
  • Adds talent to help drive Mesa’s long-term growth.

Challenges Ahead

  • Continued volatility from the COVID pandemic on both demand and supply.
  • Changing regulatory and tax environments.
  • Strong competition for attractive talent across our businesses.
  • Longer term disruptions to both component supply.
  • Disruptions to the labor markets.

Revenue & Expenses

Visualization of income flow from segment revenue to net income